<DOC>
	<DOC>NCT02099370</DOC>
	<brief_summary>The investigators are measuring the adherence rates of an oral MS drug that is to be administered twice-daily. The investigators would like to observe any patterns that might indicate factors that greatly affect adherence.</brief_summary>
	<brief_title>Adherence to Treatment With Tecfideraâ„¢ in Multiple Sclerosis Patients</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Dimethyl Fumarate</mesh_term>
	<criteria>Must give written informed consent and any authorizations required by local law (e.g., Protected Health Information [PHI]). Aged 18 at the time of informed consent. Must have a relapsing form of MS. Male subjects and female subjects of childbearing potential (including female subjects who are not postmenopausal for at least 1 year) must be willing to practice effective contraception (as defined by the investigator) during the study and be willing and able to continue contraception for 30 days after their last dose of study treatment. Progressive form of MS History of severe allergic or anaphylactic reactions or known drug hypersensitivity. Female subjects considering becoming pregnant while in the study. Female subjects who are currently pregnant or breastfeeding. Unwillingness or inability to comply with the requirements of the protocol including the presence of any conditional (physical, mental or social) that is likely to affect the subject's ability to comply with the protocol. Any other reason that, in opinion of the Investigator and/or the Sponsor, the subject is determined to be unsuitable for enrollment in this study.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Multiple Sclerosis</keyword>
	<keyword>Tecfidera(R)</keyword>
	<keyword>Oral medication</keyword>
	<keyword>Adherence</keyword>
</DOC>